High expression of dedicator of cytokinesis 1 adversely influences the prognosis of acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation
Received 31 October 2018
Accepted for publication 27 February 2019
Published 11 April 2019 Volume 2019:11 Pages 3053—3060
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Andrew Yee
Peer reviewer comments 3
Editor who approved publication: Dr Antonella D'Anneo
Gaoqi Zhang,1 Jilei Zhang,2 Xinrui Yang,1 Xinpei Zhang,1 Siyuan Yang,1 Jing Wang,1 Kai Hu,1 Jinlong Shi,3,4 Xiaoyan Ke,1 Lin Fu1
1Department of Hematology and Lymphoma Research Center, Peking University, Third Hospital, Beijing, People’s Republic of China; 2Department of Otolaryngology, Peking University People’s Hospital, Beijing 100044, People’s Republic of China; 3Department of Biomedical Engineering, Chinese PLA General Hospital, Beijing 100853, People’s Republic of China; 4Department of Medical Big Data, Chinese PLA General Hospital, Beijing 100853, People’s Republic of China
Background: Overexpression of dedicator of cytokinesis 1 (DOCK1) has been confirmed as an unfavorable prognostic marker in acute myeloid leukemia (AML).
Purpose: This study is to explore the clinical implications of DOCK1 on AML patients underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Patients and methods: We analyzed 71 de novo AML patients treated with allo-HSCT and divided them into two groups (DOCK1high, vs DOCK1low,) by the median expression level of DOCK1.
Results: High DOCK1 expression was associated with older age (P=0.019), wild-type CEBPA (P=0.002), IDH1/2 mutations (P=0.010) and RUNX1 mutation (P=0.005). Univariate analyses showed that DOCK1high, and RUNX1 mutation were associated with shorter OS (P<0.001, P=0.024). Multivariate analysis confirmed the negative effect of high DOCK1 level on overall survival (P=0.010).
Conclusion: Our results demonstrate that in AML patients who received allo-HSCT, high DOCK1 expression might have a persistent negative prognostic impact post-transplant.
Keywords: acute myeloid leukemia, allo-HSCT, DOCK1, prognosis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]